HIV/AIDS News and Research RSS Feed - HIV/AIDS News and Research Twitter

Acquired immune deficiency syndrome or acquired immunodeficiency syndrome (AIDS) is a disease of the human immune system caused by the human immunodeficiency virus (HIV).

This condition progressively reduces the effectiveness of the immune system and leaves individuals susceptible to opportunistic infections and tumors. HIV is transmitted through direct contact of a mucous membrane or the bloodstream with a bodily fluid containing HIV, such as blood, semen, vaginal fluid, preseminal fluid, and breast milk.
Cepheid, FIND announce receipt of CE-IVD status for Xpert HIV-1 Qual test

Cepheid, FIND announce receipt of CE-IVD status for Xpert HIV-1 Qual test

Cepheid and FIND today announced that Xpert HIV-1 Qual, a qualitative 90-minute molecular HIV test, has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices. [More]
DFG selects 10 researchers to receive 2015 Heinz Maier-Leibnitz Prize

DFG selects 10 researchers to receive 2015 Heinz Maier-Leibnitz Prize

This year's recipients of the most important prize for early career researchers in Germany have been announced. The selection committee, appointed by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) and the German Federal Ministry of Education and Research (BMBF), has chosen ten researchers, five women and five men, to receive the 2015 Heinz Maier-Leibnitz Prizes. [More]
Administration of selenide protects heart tissue post cardiac arrest, shows study

Administration of selenide protects heart tissue post cardiac arrest, shows study

Damage to heart muscle from insufficient blood supply during cardiac arrest and reperfusion injury after blood flow is restored can be reduced by nearly 90 percent if selenide, a form of the essential nutrient selenium, is administered intravenously in the wake of the attack, according to a new preclinical study by researchers at Fred Hutchinson Cancer Research Center. [More]
Mylan announces the U.S. launch of first generic version of Generess Fe tablets

Mylan announces the U.S. launch of first generic version of Generess Fe tablets

Mylan N.V. today announced the U.S. launch of Norethindrone and Ethinyl Estradiol Tablets (Chewable) 0.8 mg/0.025 mg and Ferrous Fumarate Tablets, 75 mg (Chewable), which is the generic version of Warner Chilcott's Generess Fe Tablets. [More]
Case Western Reserve researchers explore ways to treat, cure TB

Case Western Reserve researchers explore ways to treat, cure TB

After discovering a unique group of people resistant to tuberculosis (TB) infection, Case Western Reserve researchers are leading an international team dedicated to understanding exactly how they fight off a disease that claims 1.5 million lives each year. [More]
Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan N.V. today announced the U.S. launch of Amlodipine and Valsartan Tablets, 5 mg/160 mg, 5 mg/320 mg, 10 mg/160 mg, 10 mg/320 mg, which is the generic version of Novartis' Exforge Tablets. [More]
NYUCD receives NIH grant to develop POC test to detect HIV antibodies and viral RNA

NYUCD receives NIH grant to develop POC test to detect HIV antibodies and viral RNA

New York University College of Dentistry has received a sub-award in the amount of $335,000 from a Small Business Innovation Research (SBIR) Phase II grant from the National Institutes of Health to complete the development of a fully automated self-confirming assay that can simultaneously detect HIV/AIDS antibodies and viral RNA from the AIDS virus in a single specimen. [More]
TB Alliance, U.S. Fund for UNICEF partner to bring new TB treatments for children

TB Alliance, U.S. Fund for UNICEF partner to bring new TB treatments for children

TB Alliance has announced a new partnership with the U.S. Fund for UNICEF that will dramatically increase the scope and impact of child and maternal health programs around the world to include the diagnosis and treatment of pediatric tuberculosis (TB), a significant cause of child mortality. [More]

APM, HIV/AIDS Resource Center merge to strengthen response to HIV in Southeast Michigan

In order to strengthen the response to HIV in Southeast Michigan, AIDS Partnership Michigan and HIV/AIDS Resource Center have merged their organizations. Building on a history of collaboration and excellence, the merger of APM and HARC will ensure the sustainability of comprehensive HIV/AIDS prevention and care in their now 10-county area where 63% of people living with HIV reside. [More]
Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the European Medicines Agency has granted Advanced Therapy Medicinal Product classification for its novel stem cell drug 'Stempeucel' which will be used for the treatment of Thromboangiitis Obliterans (TAO). [More]
Janssen announces acquisition of XO1

Janssen announces acquisition of XO1

Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab. [More]
MGH study suggests that bariatric surgery can reduce risk of asthma attacks

MGH study suggests that bariatric surgery can reduce risk of asthma attacks

A study led by Massachusetts General Hospital investigators suggests that bariatric surgery can significantly reduce the risk of asthma attacks - also called exacerbations - in obese patients with asthma. [More]
GHTC report confronts key challenge of renewing US leadership in global health technology

GHTC report confronts key challenge of renewing US leadership in global health technology

‚ÄčToday, the world is looking to the United States for cutting-edge diagnostics, drugs, and vaccines that could have the last word on an Ebola outbreak that is down but not out. But those innovations are the product of past US investments in research and development (R&D). [More]
Brazil's first open-access research facility to be established at UNICAMP

Brazil's first open-access research facility to be established at UNICAMP

Open-access research into drug discovery has arrived in South America, with a ground-breaking collaboration between leading scientists in North America, Europe and Brazil to provide completely free and open research results to the world. [More]

Mylan releases Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr in U.S.

Mylan N.V. and Mylan Inc. today announced the U.S. launch of its Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr, adding to its existing offering of Fentanyl Transdermal System 12, 25, 50, 75 and 100 mcg/hr. [More]
Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit. [More]
Simple low-cost intervention could help reduce HIV-related deaths in Africa

Simple low-cost intervention could help reduce HIV-related deaths in Africa

A new approach to care for patients with advanced HIV in Tanzania and Zambia, combining community support and screening for a type of meningitis, has reduced deaths by 28%. [More]
Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Officials from the National Institutes of Health and the city of Washington, D.C., launched a clinical trial to examine whether primary care physicians and other health care providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection. [More]
Lifestyle intervention program at workplace reduces risk factors for diabetes, heart disease

Lifestyle intervention program at workplace reduces risk factors for diabetes, heart disease

A healthy lifestyle intervention program administered at the workplace and developed by the University of Pittsburgh Graduate School of Public Health significantly reduces risk factors for diabetes and heart disease, according to a study reported in the March issue of the Journal of Occupational and Environmental Medicine. [More]
Women for Positive Action introduces new educational tool for women living with HIV

Women for Positive Action introduces new educational tool for women living with HIV

To mark International Women's Day (March 8, 2015), Women for Positive Action has launched a practical and informative new educational tool entitled 'Hepatitis and coinfection in women living with HIV'. Led by a global, multidisciplinary group of experts, Women for Positive Action is committed to addressing the specific concerns of women living with HIV. [More]
Advertisement